Von Hippel-Lindau disease: pathophysiological and clinical advances

S. J. van Alfen, K. van der Tuin, B. van de Kooij, T. P. Links, W. T. Zandee · 2026

Read Von Hippel-Lindau disease: pathophysiological and clinical advances by S. J. van Alfen, K. van der Tuin, B. van de Kooij, T. P. Links, W. T. Zandee (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13279576.txt.

Description

S. J. van Alfen and colleagues give a 2026 review of Von Hippel Lindau disease, a rare inherited tumour syndrome. A fault in the VHL gene, passed in families, raises risk of tumours in kidney, eye, brain, pancreas and adrenal glands. Loss of the gene lets low oxygen signal proteins, called HIF, build up. Those signals drive vessel growth and red cell making, which feed tumours.

A drug that blocks the HIF two alpha part, belzutifan, marks a major step in care. Health agencies in the United States and Europe have approved it for a range of tumours from this disease. New work shows the VHL protein also has jobs past HIF control. Loss of those jobs may add to tumour growth. The review maps both the classic path and the new leads.

Catalog record

CREATORS. J. van Alfen, K. van der Tuin, B. van de Kooij, T. P. Links, W. T. Zandee
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE43130
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13279576

Browse the full library · About the Tower of Babel